Compare iShares China Large-Cap ETF (FXI) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs GE HealthCare Technologies Inc. Common Stock — how do they compare? iShares China Large-Cap ETF trades at $33.93 (market cap $3.90B), while GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 7.9× iShares China Large-Cap ETF's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals.
| FXI | GEHC | |
|---|---|---|
Market Cap | $3.90B | $30.93B |
Volume | 21,620,520 | 5,033,451 |
52-Week High | $41.08 | $88.16 |
52-Week Low | $31.59 | $59.48 |
Typical Hold Time | 151 Days | — |
Sector | — | Health |
Enterprise Value | — | $39.39B |
Dividend Yield | — | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $34.17 with minimal daily movement (+0.09%). The technical picture is bearish with moving averages signaling caution, though oscillators are neutral. Recent news highlights China's economic challenges including industrial overcapacity and weak domestic consumption, while corporate profits surged 26% in Q2 2026. The ETF trades at a significant discount to U.S. equities with a P/E of 11.10 versus the S&P 500's 22.54, offering potential value amid high political risk.
FXI presents a contrarian opportunity for investors seeking China exposure at discounted valuations, but faces substantial headwinds from U.S.-China tensions and domestic economic rebalancing. The ETF's heavy financial sector weighting and state-backed monetary support provide stability, though momentum remains weak. Key risks include escalating trade protectionism and China's export control uncertainties.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
